Morgan Stanley analyst Kallum Titchmarsh assumed coverage of Treace Medical (TMCI) with an Equal Weight rating and an unchanged price target of $7.50. The firm cites limited visibility on competitive headwinds and utilization.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical price target raised to $8 from $7 at Stifel
- Treace Medical Concepts Reports Strong Q3 2024 Growth
- Closing Bell Movers: Exact Sciences falls 30% after results, guidance cut
- Treace Medical reports Q3 EPS (25c), consensus (27c)
- Treace Medical comments on CMS final rule for hospital outpatient, ASC settings